Anika Therapeutics (ANIK) Revenue (2010 - 2026)

Anika Therapeutics (ANIK) has 17 years of Revenue data on file, last reported at $29.6 million in Q1 2026.

• Revenue for Q1 2026 came in at $29.6 million, up 13.16% year-over-year; the trailing twelve-month figure through Mar 2026 was $116.3 million (down 0.67% YoY), and the FY2025 annual result was $112.8 million, down 5.91% from the prior year.
• Revenue fell to $29.6 million in Q1 2026 per ANIK's latest filing, from $30.6 million in the prior quarter.
• Over five years, Revenue peaked at $44.3 million in Q2 2023 and troughed at -$2.9 million in Q4 2023.
• A 5-year average of $29.2 million and a median of $30.6 million in 2024 frame the typical range for Revenue.
• The sharpest annual moves came in 2022 and 2024: Revenue plunged 107.78% in 2022, then soared 1155.61% in 2024.
• A 5-year view of Revenue shows it stood at -$2.8 million in 2022, then retreated by 4.02% to -$2.9 million in 2023, then soared by 1155.61% to $30.6 million in 2024, then gained by 0.04% to $30.6 million in 2025, then slipped by 3.28% to $29.6 million in 2026.
• Business Quant data shows ANIK's Revenue at $29.6 million in Q1 2026, $30.6 million in Q4 2025, and $27.8 million in Q3 2025.